Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 38

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
 Weighted average common shares outstanding:     Basic46,275 46,499      Diluted46,526 52,193     

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 5

Table of Contents

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

Three Months EndedMarch 31, 20252024Net income$4,812 $8,979 Other comprehensive income (loss):  Net unrealized loss on investments, net of tax(86)(108)Foreign currency translation adjustments1,094 13 Total other comprehensive income (loss)1,008 (95)Comprehensive income$5,820 $8,884 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 6

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024

(In thousands)

(Unaudited)

 Number of Shares OutstandingAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome  Common SharesTreasury SharesCommon StockTreasury StockTotalBalance at December 31, 202447,078 (837)$47 $(25,121)$1,009,435 $(206,356)$343 $778,348 Vested restricted stock units53 — — — 1 — — 1 Common stock withheld for employee withholding tax liabilities on vested restricted stock units(10)— — — (181)— — (181)Stock-based compensation— — — — 14,553 — — 14,553 Other comprehensive income (Note 11)— — — — — — 1,008 1,008 Net income— — — — — 4,812 — 4,812 Balance at March 31, 202547,121 (837)$47 $(25,121)$1,023,808 $(201